Download presentation
Presentation is loading. Please wait.
1
Peptidna bioregulacija
RUSKI PEPTIDI
2
Khavinson Vladimir Khatskelevich
Director of St.Petersburg Institute of Bioregulation and Gerontology of the North Western Dpt. of the Russian Academy of Medical Sciences Associate Member of the Russian Academy of Medical Sciences, professor, Doctor of Medicine Honored Scientist of the Russian Federation, Honored Inventor of the Russian Federation President of International Association of Gerontology and Geriatrics, European Region Vice-president of Gerontological Society of the Russian Academy of Medical Sciences Chief gerontologist of the Health Committee of the Government of St.Petersburg Member of Expert Council of the Public Chamber of the Russian Federation Member of Expert Council of the Higher Attestation Commission (VAK) The USSR Council of Ministers' Prize winner, The Ukrainian Academy of Medical Sciences Prize winner, The Ukrainian National Academy of Sciences Prize winner Paul Ehrlich Medal winner for outstanding achievements in preventive and social medicine, Europäische Akademie der Naturwissenschaften The author of over 700 scientific publications, including 27 monographs, domestic and international patents The inventor of 6 pharmaceuticals and 39 peptide bioregulators
3
Quality of the products is guaranteed by the principles of qualitative manufacturing practice "Chemico-Biological Association under the Russian Academy of Medical Sciences "Firma Vita", Ltd. Highly qualified specialists The modern system of quality control at all production stages "Peptide- Bio" product line is produced under the control of developer: St.Petersburg Institute of Bioregulation and Gerontology of the North Western Dpt. of the Russian Academy of Medical Sciences
4
Peptide Bio product line
Cardiogen Peptide for cardiovascular system Normoftal Peptide for visual organs Bronchogen Peptide for bronchopulmonary system Testagen Peptide for men’s sexual function improvement Pancragen Peptide for pancreas Vesilut Peptide for urinary system 4
5
The composition of the latest generation of peptide bioregulators
Products are obtained by biological synthesis NORMOFTAL® AKS-G complex (lysine, glutamic acid) BRONHOGEN® AKS-B complex (alanine, glutamic acid, aspartic acid, leucine) KARDIOGEN® AKS-K complex (alanine, glutamic acid, aspartic acid, arginine) VEZILYUT® AKS-M complex (glutamic acid, aspartic acid) TESTAGEN® AKS-S complex (lysine, glutamic acid, aspartic acid, glycine) PANKRAGEN® AKS-P complex (lysine, glutamic acid, aspartic acid, tryptophan)
6
of peptide bioregulators
Epigenomic effect of peptide bioregulators The scheme of the local separation of chains [poly(dAdT):poly(dAdT)] in consequence of binding of peptide bioregulator Ala-Glu-Asp-Gly in the major groove of a DNA double helix
7
General action mechanism of peptide bioregulators
Proliferation Mitosis Protein synthesis Restored cell Damaged cell Peptide bioregulators penetrate into the damaged cells, eliminate the point mutations, stimulate the restoration of the protein synthesis intensity and regulate the expression of genes responsible for cells differentiation and proliferation. As a result, in the target tissue proceed the proliferation of morphologically mature cells with the optimal metabolism level.
8
The cellular effects of peptide bioregulators
A complementary interaction between short peptides and DNA Chromatin decondensation Change in genes conformation and expression Tissue-specific proteins synthesis Cellular proliferation and differentiation Regulation of biochemical and physiological processes
9
Mechanism of a short peptide intracellular delivery
PEPTIDE BIOREGULATOR ПЕПТИДНЫЙ БИОРЕГУЛЯТОР Small intestine Portal vein/liver Target organ Cell
10
The cellular effects of peptide bioregulators. Summary.
While getting into the nucleus of cells and interacting with specific chromatin loci, the PB regulate the most important steps in the genetic program implementation, such as: the optimal rate of stem cells division the maturation of low-differentiated precursor cells with the acquirement of mature cells properties the maintaining of an optimal range of specific enzymes and receptors in mature cells, thereby regulating their functional state support of non-specific protective and reparative intracellular systems activity, thereby enhancing cell viability and reducing the apoptosis rate in both normal and pathological conditions
11
The tissue effects of peptide bioregulators. Part 1.
Application of peptide bioregulators allows to optimize the tissue and organic regeneration. An optimization includes: - the support of the organ or tissue integrity in normal conditions; - fast and effective recovery from acute or chronic effect of external damaging factors; - significant reduction in capacity or development rate of pathological regeneration, such as fibrosis, dysplasia, metaplasia, and others Peptide bioregulators have a protective effect on complementary (TARGET) tissues. It leads to the increase of cells resistance under hypoxic conditions, the toxic effects and other damaging factors. This effect is associated with maintain of a high level of cellular reparative and antioxidant systems activity, and also with number of non-specific protective factors, particularly with the intracellular pool of glutathione.
12
The tissue effects of peptide bioregulators. Part 2.
Peptide bioregulators normalize the tissues metabolism and maintain the optimal number and spectrum of receptors and enzymes in cells. It exerts an influence on the efficiency of nutrients assimilation in tissues and metabolic products removal. Peptide bioregulators have an effect on the complementary organs and tissues functional activity in both normal and pathological conditions. Peptide bioregulators maintain the metabolism and the optimal number of mature and functionally active cells. It provides the base for: 1) an effective integration of organs and tissues at the level of the entire organism under the influence of other endogenous regulatory systems; 2) an adequate functional adaptation of organs and tissues to the changing needs of the organism.
13
The place of the peptide bioregulators in the therapeutic paradigm
Contemporary therapeutic treatment regimens: combination of drug therapy, diet and recommendations for lifestyle changes The model of the treatment regimens development: «Another brick in the wall» – the missing link Anabolic β-blocker ? ACE inhibitor Low molecular heparine Statine
14
peptide bioregulators
Cardiology: For example: CHD + arterial hypertension + hypercholesterolemia + CHF Vasodilators (В, А, А+В) Statins and fibrates Diuretics Central neurotropic agents Antiplatelet agents β-Blockers ACE inhibitors Organo-specific peptide bioregulators Angiotensin I receptor antagonists Calcium channel blockers Peripheral neurotropic agents Anticoagulants
15
Pulmonology: For example: COPD
Detoxication (tobacco, industrial poisons) Antibiotics Fluoroquinolones Bronchodilators: М-acetylcholine receptor antagonists Indirect mucokinetics Bronchodilators: β2-adrenergic agonists Phospholipase A2 inhibitors Topical steroids Systemic glucocorticoids Organo-specific peptide bioregulators Direct mucokinetics (enzymes)
16
Urology: For example: andropause, spermatogenesis disorders
Urological disorders therapy Nervous disorders therapy Detoxication (tobacco, alcohol) Diabetes therapy Hormonal replacement therapy Organo-specific peptide bioregulators Metabolic syndrome therapy Cardiovascular diseases therapy PDE5 inhibitors
17
Endocrinology: For example: the metabolic syndrome, type 2 diabetes
DIET SPORTS Thiazolidinediones (pioglitazone) Biguanides (metformin) Alpha-glucosidase inhibitors Organo-specific peptide bioregulators Second-generation sulfonylurea medications Secretagogues (repaglinide) Incretin mimetics B group vitamins
18
The main directions of peptide bioregulators application
Treatment: inclusion in the treatment regimens Post- disease rehabilitation Administration to healthy persons, prolongation of the working ability period Geroprotection + prescription to the elderly Peptide bioregulators Treatment: inclusion in the treatment regimens Post- disease rehabilitation Administration to healthy persons, prolongation of the working ability period Geroprotection + prescription to the elderly Peptide bioregulators
19
Peptide bioregulators dosage
The preventive dosage is one capsule two times a day. Сourse of administration is 60 days. Curative dosage is two capsules two times a day. Сourse of administration is from 60 to 120 days, depends on initial patient’s condition. Dosage recommendations may vary widely. It depends on diagnosis and method of application, such as: health improvement, prophylaxis or the inclusion in the treatment regimens.
20
Peptide bioregulators - 2011
Synthesized products exclude the presence of prions and latent or active viruses exposing to risk of infectious diseases High purity of a substance Tissue-specific and organo-specific properties Don’t provide any stimulation or depression effects on cellular metabolism Hypoallergenic. No side effects Supplement of treatment regimen, increase of treatment effect, compatibility with all medications Can be taken without a prescription Made in Russia. Patented in 13 countries The absence of direct competitive products Bioregulatory therapy is one of the fundamental directions of pharmacology development in area of work-status longevity
21
Therapeutic combinations of peptide regulators / type 2 diabetes
Pancragen Degenerative lesions of the Langerhans islets and acinar tissue Normoftal Diabetic retinopathy, autonomic neuropathy Type 2 diabetes Coronary heart disease. Peripheral vascular atherosclerosis Cardiogen Diabetic nephropathy + pyelonephritis Vesilut
22
Therapeutic combinations of peptide regulators / COPD
Focal atrophy of the bronchial epithelium Bronchogen COPD Pneumosclerosis Cardiogen Cor pulmonale. Pulmonary heart disease Pancragen Hypoxic damage of parenchymal organs
23
Therapeutic combinations of peptide regulators / CAD
Cardiosclerosis Cardiogen Atherosclerosis. CAD. CHF Normoftal Cerebrovascular disease Bronchogen Pulmonary perfusion disturbance Pancragen Hypoxic damage of parenchymal organs
24
Therapeutic combinations of peptide regulators / andropause
Testagen Testosterone level decrease Andropause. BPH Normoftal Erectile dysfunction (with combined genesis) Pancragen Impaired glucose tolerance BPH. Urination disorders Vesilut
25
The benefits of peptide bioregulators
Peptides are obtained by biological synthesis. It excludes the presence of prions, latent or active viruses and ensures a high purity of substance The substance is identical to the native peptide. As a result, the peptide bioregulators are hypoallergenic, safe in a wide range of doses and have no side effects The range of application is: health improvement, prophylaxis, monotherapy or the inclusion in the treatment regimens. It allows to create an individual dosage for each customer and patient Application of peptide regulators leads to a stable long-term results, increases the conventional therapy effectiveness and improves the life quality of the consumer or patient
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.